Commentary on the EMA Guideline on Strategies to Identify and Mitigate Risks for First-in-human and Early Clinical Trials with Investigational Medicinal Products

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2018 Feb 17

PMID 29451320

Citations 92

Authors

Joop van Gerven

Milton Bonelli

Affiliations

Soon will be listed here.

Citing Articles

SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols.

Ursino M, Villacampa G, Rekowski J, Dimairo M, Solovyeva O, Ashby D EClinicalMedicine. 2025; 79:102988.

PMID: 39877554 PMC: 11773215. DOI: 10.1016/j.eclinm.2024.102988.

CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials.

Rekowski J, Guo C, Solovyeva O, Dimairo M, Rouhifard M, Patel D EClinicalMedicine. 2025; 79:102987.

PMID: 39877553 PMC: 11773258. DOI: 10.1016/j.eclinm.2024.102987.

Synthesizing regulatory guidance for demonstrating preclinical efficacy and translating promising cell therapies to early phase clinical trials: a scoping review.

Jeffers M, Xi C, Bapuji R, Wotherspoon H, Kimmelman J, Bedford P BMC Med. 2024; 22(1):487.

PMID: 39443960 PMC: 11515533. DOI: 10.1186/s12916-024-03690-8.

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.

Carretero-Iglesia L, Hall O, Berret J, Pais D, Estoppey C, Chimen M Nat Cancer. 2024; 5(10):1494-1514.

PMID: 39261676 PMC: 11505469. DOI: 10.1038/s43018-024-00821-1.

Phase 0 trials/ Intra-Target-Microdosing (ITM) and the lung: a review.

Quinn T, Bruce A, Burt T, Dhaliwal K BMC Pulm Med. 2024; 24(1):425.

PMID: 39210357 PMC: 11363577. DOI: 10.1186/s12890-024-03193-5.

References

van Gerven J, Cohen A . Integrating data from the Investigational Medicinal Product Dossier/investigator's brochure. A new tool for translational integration of preclinical effects. Br J Clin Pharmacol. 2018; 84(7):1457-1466. PMC: 6005609. DOI: 10.1111/bcp.13529. View

van Gerven J, Bonelli M . Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. Br J Clin Pharmacol. 2018; 84(7):1401-1409. PMC: 6005602. DOI: 10.1111/bcp.13550. View

Kerbrat A, Ferre J, Fillatre P, Ronziere T, Vannier S, Carsin-Nicol B . Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase. N Engl J Med. 2016; 375(18):1717-1725. DOI: 10.1056/NEJMoa1604221. View

Kenter M, Cohen A . Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet. 2006; 368(9544):1387-91. DOI: 10.1016/S0140-6736(06)69562-7. View

Morgan P, van der Graaf P, Arrowsmith J, Feltner D, Drummond K, Wegner C . Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today. 2012; 17(9-10):419-24. DOI: 10.1016/j.drudis.2011.12.020. View

Zhang D, Saraf A, Kolasa T, Bhatia P, Zheng G, Patel M . Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets. Neuropharmacology. 2007; 52(4):1095-105. DOI: 10.1016/j.neuropharm.2006.11.009. View

Brynne L, Bresell A, Sjogren N . Effective visualization of integrated knowledge and data to enable informed decisions in drug development and translational medicine. J Transl Med. 2013; 11:250. PMC: 3842641. DOI: 10.1186/1479-5876-11-250. View

Horvath C, Milton M . The TeGenero incident and the Duff Report conclusions: a series of unfortunate events or an avoidable event?. Toxicol Pathol. 2009; 37(3):372-83. DOI: 10.1177/0192623309332986. View

Brosen K, Funck-Brentano C, Kroemer H, Pirmohamed M, Schwab M . Open letter on access to the BIA 10-2474 clinical trial data. Lancet. 2016; 389(10065):156. DOI: 10.1016/S0140-6736(16)32515-6. View

10.

Cohen A, Burggraaf J, van Gerven J, Moerland M, Groeneveld G . The use of biomarkers in human pharmacology (Phase I) studies. Annu Rev Pharmacol Toxicol. 2014; 55:55-74. DOI: 10.1146/annurev-pharmtox-011613-135918. View

11.

van Iersel M, Greenberg H, Westrick M . Structured Risk Assessment for First-in-Human Studies. Ther Innov Regul Sci. 2018; 51(3):288-297. DOI: 10.1177/2168479017705156. View

12.

Bonini S, Rasi G . First-in-Human Clinical Trials - What We Can Learn from Tragic Failures. N Engl J Med. 2016; 375(18):1788-1789. DOI: 10.1056/NEJMe1609006. View

13.

van Esbroeck A, Janssen A, Cognetta 3rd A, Ogasawara D, Shpak G, van der Kroeg M . Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science. 2017; 356(6342):1084-1087. PMC: 5641481. DOI: 10.1126/science.aaf7497. View

14.

den Elzen W, van Gerven J, Schenk P, Uit den Boogaard A, Kroon R, Klaassen E . How to define reference intervals to rule in healthy individuals for clinical trials?. Clin Chem Lab Med. 2016; 55(3):e59-e61. DOI: 10.1515/cclm-2016-0307. View

15.

Fruhner K, Hartmann G, Sudhop T . Analysis of integrated clinical trial protocols in early phases of medicinal product development. Eur J Clin Pharmacol. 2017; 73(12):1565-1577. PMC: 5684304. DOI: 10.1007/s00228-017-2335-y. View

16.

Higgins J . Normal resting electrocardiographic variants in young athletes. Phys Sportsmed. 2010; 36(1):69-75. DOI: 10.3810/psm.2008.12.14. View

17.

Eddleston M, Cohen A, Webb D . Implications of the BIA-102474-101 study for review of first-into-human clinical trials. Br J Clin Pharmacol. 2016; 81(4):582-6. PMC: 4799914. DOI: 10.1111/bcp.12920. View

18.

Kenter M, Cohen A . The return of the prodigal son and the extraordinary development route of antibody TGN1412 - lessons for drug development and clinical pharmacology. Br J Clin Pharmacol. 2015; 79(4):545-7. PMC: 4386939. DOI: 10.1111/bcp.12605. View

19.

Breithaupt-Groegler K, Coch C, Coenen M, Donath F, Erb-Zohar K, Francke K . Who is a 'healthy subject'?-consensus results on pivotal eligibility criteria for clinical trials. Eur J Clin Pharmacol. 2017; 73(4):409-416. PMC: 5350217. DOI: 10.1007/s00228-016-2189-8. View

20.

Prowell T, Theoret M, Pazdur R . Seamless Oncology-Drug Development. N Engl J Med. 2016; 374(21):2001-3. DOI: 10.1056/NEJMp1603747. View